Enfusion Inc. (ENFN)
NYSE NYSE Primary 
ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
An Investigation Has Commenced on Behalf of Enfusion, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ENFN Losses.
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Stockholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Enfusion: Growth Should Accelerate In Coming Quarters
ENFN's Q2 2024 earnings show growth in revenue and margins, with potential for growth acceleration in the future. ENFN is successfully penetrating new markets and upmarket, despite challenges in the macro environment. The key to ENFN's positive rerating lies in reaccelerating growth and improving profitability.
Enfusion Inc Investors Encouraged To Join Securities Fraud Investigation Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Enfusion, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Enfusion (ENFN)
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Stockholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Investors Who Lost Money In Enfusion Inc Invited To Join Securities Fraud Investigation Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ENFN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Enfusion Inc Shareholders Invited To Participate In Securities Fraud Investigation Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Enfusion Inc Investors Encouraged To Join Securities Fraud Investigation Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
